Table 2.
MR results of the causal effect of MMP-3 on ER-negative BC.
| Exposure | Outcome | No. of SNPs | Method | OR (95% CI) | P value | Heterogeneity | Pleiotropy | |
|---|---|---|---|---|---|---|---|---|
| Cochrane's Q | P | P | ||||||
| MMP3 |
ER- Breast cancer (Experimental set) |
12 | MR Egger | 1.08(0.91–1.29) | 0.39 | 35.30 | < 0.01 | 0.37 |
| Weighted median | 1.03(0.96–1.11) | 0.38 | ||||||
| Inverse variance weighted | 1.01(0.93–1.09) | 0.88 | 38.39 | < 0.01 | ||||
| Simple mode | 0.94(0.81–1.09) | 0.42 | ||||||
| Weighted mode | 1.04(0.98–1.10) | 0.22 | ||||||
| MMP3 |
ER- Breast cancer (Validation set1) |
12 | MR Egger | 1.12(0.95–1.31) | 0.20 | 15.01 | 0.13 | 0.13 |
| Weighted median | 1.02(0.92–1.13) | 0.74 | ||||||
| Inverse variance weighted | 0.99(0.91–1.08) | 0.88 | 19.16 | 0.06 | ||||
| Simple mode | 0.93(0.76–1.14) | 0.49 | ||||||
| Weighted mode | 1.06(0.97–1.16) | 0.24 | ||||||
| MMP3 |
ER- Breast cancer (Validation set2) |
12 | MR Egger | 1.00(0.73–1.37) | 0.98 | 39.28 | < 0.01 | 0.96 |
| Weighted median | 1.02(0.93–1.13) | 0.63 | ||||||
| Inverse variance weighted | 0.99(0.86–1.14) | 0.88 | 39.29 | < 0.01 | ||||
| Simple mode | 1.01(0.84–1.21) | 0.92 | ||||||
| Weighted mode | 1.02(0.94–1.11) | 0.62 | ||||||
| MMP3 |
ER- Breast cancer (Validation set3) |
12 | MR Egger | 1.15(0.91–1.46) | 0.26 | 8.84 | 0.55 | 0.54 |
| Weighted median | 1.08(0.95–1.23) | 0.27 | ||||||
| Inverse variance weighted | 1.08(0.97–1.20) | 0.17 | 9.25 | 0.60 | ||||
| Simple mode | 0.97(0.75–1.26) | 0.83 | ||||||
| Weighted mode | 1.07(0.93–1.24) | 0.36 | ||||||
| MMP3 |
ER- Breast cancer (Validation set4) |
12 | MR Egger | 1.00(0.78–1.29) | 0.97 | 24.54 | < 0.01 | 0.97 |
| Weighted median | 1.01(0.92–1.12) | 0.81 | ||||||
| Inverse variance weighted | 1.00(0.89–1.12) | 1.00 | 24.55 | 0.01 | ||||
| Simple mode | 1.00(0.83–1.21) | 0.99 | ||||||
| Weighted mode | 1.02(0.93–1.12) | 0.61 | ||||||
BC breast cancer; CI, confidence interval; ER estrogen receptor; MMP Matrix metalloproteinases; MR Mendelian randomization; OR Odds ratio; SNP Single nucleotide polymorphisms.